Monash IVF (MVF) says the IVF market is recovering

Monash IVF (ASX:MVF) shares are down 1% despite announcing that it is seeing a recovery in the IVF market. 

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

Monash IVF (ASX: MVF) shares are down 1% despite announcing that it is seeing a recovery in the IVF market.

What is Monash IVF?

Monash IVF Group is a leading provider of assisted reproductive services. Basically, they assist couples who wish to have children but for one reason or another, have difficulty in conceiving a child naturally. Technology has come a long way since the first IVF pregnancy back in 1973 and Monash IVF is at the forefront of these developments.

What did the company announce?

Monash IVF said that there has been pent up patient demand after IVF treatments restarted on 27 April 2020. Compared to the prior corresponding period and pre-COVID-19 levels, the company has seen strong growth.

From 18 May 2020 to 30 June 2020 the company has seen stimulated cycle growth of 25%. There has been growth across all key markets in Australia. The company is also pleased by positive early signs from the new patient pipeline returning to normal levels.

The company’s women’s ultrasound business remained open during April, May and June. Ultrasound can volumes were down around 5% compared to a year ago. However, strict infection control and hygiene measures has increased costs.

Internationally, the Malaysian IVF business is still being impacted by restrictions, though these were eased on 9 June 2020. Trading conditions are improving, but still yet to return to pre COVID-19 levels.

At 30 June 2020 the company is expecting net debt to be less than $10 million after its recent $80 million capital raising. The company will pay its deferred HY20 dividend on 2 October 2020.

The company expects the second half of FY20 to show adjusted profit of $4.6 million, down 55% because of COVID-19. Therefore, the company is expecting adjusted FY20 net profit to be $14 million.

I’m glad to see that the company is recovering, but I’m not sure if I’d invest in it. Cheap IVF competition is rising and an Australian recession could dent medium term IVF demand.

[ls_content_block id=”14945″ para=”paragraphs”]

Disclosure: At the time of writing, Jaz doesn’t own shares in any of the businesses mentioned. 

online pharmacy buy avodart online with best prices today in the USA
online pharmacy buy doxycycline no prescription with best prices today in the USA

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.